Cantor Fitzgerald has chosen AVITA Medical (NASDAQ:RCEL) as its “best idea” for medtech for 2024 while remaining bullish on Axogen (NASDAQ:AXGN), Cerus (NASDAQ:CERS), Elutia (ELUT), Exagen (XGN), NANO-X (NNOX), NeuroPace (NPCE), Nyxoah (NYXH), SI-BONE (SIBN) and Pacific Biosciences (NASDAQ:PACB).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.